The effects of selective cytokine inhibitory drugs (CC-10004 and CC-1088) on VEGF and IL-6 expression and apoptosis in myeloma and endothelial cell co-cultures

British Journal of Haematology

Volumn 124, Issue 3, 2004, Pages 366-375

  Molostvov, G ^a   Morris, A ^b   Rose, P ^c   Basu, S ^c   Muller, G ^d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c WARWICK HOSPITAL   (United Kingdom)

^d CELGENE CORPORATION   (United States)

Author keywords

Interleukin 6; Myeloma; Selective cytokine inhibitory drugs; Thalidomide; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; CC 10004; CC 1088; INTERLEUKIN 6; PHOSPHODIESTERASE IV INHIBITOR; THALIDOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL INTERACTION; CELL PROTECTION; COCULTURE; CONTROLLED STUDY; DRUG POTENCY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MYELOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; APOPTOSIS; COCULTURE TECHNIQUES; CYTOKINES; DEPRESSION, CHEMICAL; ENDOTHELIAL CELLS; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; THALIDOMIDE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0842287256     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2003.04777.x     Document Type: Article

References (45)

1. Bataille, R., Jourdan, M., Zhang, X.G. & Klein, B. (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2011.
2. Bellamy, W.T., Richter, L., Frutiger, Y. & Grogan, T.M. (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research, 59, 728-733.
3. Bloem, A.C., Lamme, T., De Smet, M., Kok, H., Vooijs, W., Wijdenes, J., Boom, S. & Lokhorst, H.M. (1998) Long-term bone marrow cultured stromal cells regulate myeloma tumour growth in vitro: studies with primary tumour cells and LTBMC-dependent cell lines. British Journal of Haematology, 100, 166-175.
4. Chauhan, D. & Anderson, K.C. (2003) Mechanisms of cell death and survival in multiple myeloma: therapeutic implications. Apoptosis, 8, 337-343.
5. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T.A. & Anderson, K.C. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood, 87, 1104-1112.
6. Corral, L.G., Haslett, P.A.J., Muller, G.W., Chen, R., Wong, L.M., Ocampo, C.J., Patterson, R.T., Stirling, D.I. & Kaplan, G. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α. Journal of Immunology, 163, 380-386.
7. D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 4082-4085.
8. Dankbar, B., Padro, T., Leo, R., Feldmann, B., Kropff, M., Mesters, R.M., Serve, H., Berdel, W.E. & Kienast, J. (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumorstromal interaction in multiple myeloma. Blood, 95, 2630-2636.
9. Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. & Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210-216.
10. Diggle, G.E. (2001) Thalidomide: 40 years on. International Journal of Clinical Practice, 55, 627-631.
11. Geitz, H., Handt, S. & Zwingenberger, K. (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 31, 213-221.
12. Gupta, D., Treon, S.P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.T., Lin, B., Lentzsch, S., Davies, F.E., Chauhan, D., Schlossman, R.L., Richardson, P., Ralph, P., Wu, L., Payvandi, F., Muller, G., Stirling, D.I. & Anderson, K.C. (2001) Adherence of multiple myeloma cells to bone marrow stromal cells up-regulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia, 15, 1950-1961.
13. Haslett, P.A.J., Corral, L.G., Albert, M. & Kaplan, G. (1998) Thalidomide co-stimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production and cytotoxic responses in the CD8+ subset. Journal of Experimental Medicine, 187, 1885-1892.
14. Hayashi, T., Hideshima, T. & Anderson, K.C. (2003) Novel therapies for multiple myeloma. British Journal of Haematology, 120, 10-17.
15. Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. & Anderson, K.C. (2000) Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943-2950.
16. Hideshima, T., Chauhan, D., Podar, K., Schlossman, R.L., Richardson, P. & Anderson, K.C. (2001) Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology, 28, 607-612.
17. Hideshima, T., Richardson, P. & Anderson, K.C. (2003) Novel therapeutic approaches for multiple myeloma. Immunology Reviews, 194, 164-176.
18. Imaizumi, T., Itaya, H., Nasu, S., Yoshida, H., Matsubara, Y., Fujimoto, K., Matsumiya, T., Kimura, H. & Satoh, K. (2000) Expression of vascular endothelial growth factor in human umbilical vein endothelial cells stimulated with interleukin-1alpha - an autocrine regulation of angiogenesis and inflammatory reactions. Thrombosis and Haemostasis, 83, 949-955.
19. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O. & Tanaka, H. (1988) Autocrine generation and essential requirement BSF-2/IL-6 for human multiple myeloma. Nature, 332, 83-85.
20. Klein, B., Zhang, X.G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. & Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517-526.
21. Klein, B., Zhang, X.G., Lu, Z.Y. & Bataille, R. (1995) Interleukin-6 in human multiple myeloma. Blood, 85, 863-872.
22. Kneller, A., Raanani, P., Hardan, I., Avigdor, A., Levi, I., Berkowicz, M. & Ben-Bassat, I. (2000) Therapy with thalidomide in refractory multiple myeloma patients - the revival of an old drug. British Journal of Haematology, 108, 391-393.
23. Kyle, R.A. & Rajkumar, S.V. (2001) Therapeutic application of thalidomide in multiple myeloma. Seminars in Oncology, 28, 583-587.
24. Levy, Y., Labaume, S., Colombel, M. & Brouet, J.C. (1996) Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis. Clinical Experimental Immunology, 104, 167-172.
25. Lokhorst, H.M., Lamme, T., De Smet, M., Klein, S., De Weger, R.A., van Oers, R. & Bloem, A.C. (1994) Primary tumour cells of myeloma patients induce IL-6 secretion in long term bone marrow cultures. Blood, 84, 2269-2277.
26. Ludwig, H., Nachbaur, D.M., Fritz, E., Krainer, M. & Huber, H. (1991) Interleukin-6 is a prognostic factor in multiple myeloma. Blood, 77, 2794-2795.
27. Merico, F., Bergui, L., Gregoretti, M.G., Ghia, P., Aimo, G., Lindley, I.J. & Caligaris-Cappio, F. (1993) Cytokines involved in the progression of multiple myeloma. Clinical Experimental Immunology, 92, 27-31.
28. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. & Anderson, K.C. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, 4525-4530.
29. Molostvov, G., Morris, A., Rose, P. & Basu, S. (2002) Interactions between myeloma and endothelial cells and the effects of thalidomide and its analogues. In: 7th Annual Meeting of the European Haematology Association. Free Papers, pp. 263-266. Monduzzi Editore, Florence.
30. Moreira, A.L., Friedlander, D.R., Shif, B., Kaplan, G. & Zagzag, D. (1999) Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro. Journal of Neuro-oncology, 43, 109-114.
31. Morgan, G.J. (1999) Advances in the biology and treatment of myeloma. British Journal of Haematology, 105(Suppl. 1), 4-6.
32. Nishimoto, N., Ogata, A., Shima, Y., Tani, Y., Ogawa, H., Nakagawa, M., Sugiyama, H., Yoshizaki, K. & Kishimoto, T. (1994) Oncostatin M, leukemia inhibitory factor, and interleukin-6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. Journal of Experimental Medicine, 179, 1343-1347.
33. Podar, K., Tai, Y.T., Davies, F.E., Lentzsch, S., Sattler, M., Hideshima, T., Lin, B.K., Gupta, D., Shima, Y., Chauhan, D., Mitsiades, C., Raje, N., Richardson, P.I. & Anderson, K.C. (2001) Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood, 98, 428-435.
34. Portier, M., Rajzbaum, G., Zhang, X.G., Attal, M., Rusalen, C., Wijdenes, J., Mannoni, P., Maraninchi, D., Piechaczyk, M. & Bataille, R. (1991) In vivo interleukin 6 gene expression in the tumoral environment in multiple myeloma. European Journal of Immunology, 21, 1759-1762.
35. Rajkumar, S.V. & Witzig, T.E. (2000) A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treatment Reviews, 26, 351-362.
36. Ribatti, D., Vacca, A., Nico, B., Quondamatteo, F., Ria, R., Minischetti, M., Marzullo, R., Herken, R., Roncali, L. & Dammacco, F. (1999) Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. British Journal of Cancer, 79, 451-455.
37. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., LeBlanc, R., Catley, L.P., Doss, D., Kelly, K., McKenney, M., Mechlowicz, I., Freeman, A., Deocampo, R., Rich, R., Ryoo, J.J., Chauhan, D., Balinski, K., Zeldis, J. & Anderson, K.C. (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063-3067.
38. Sampaio, E.P., Sarno, E.N., Galilly, R., Cohn, Z.A. & Kaplan, G. (1991) Thalidomide selectively inhibits tumour necrosis factor-alpha production by stimulated human monocytes. Journal of Experimental Medicine, 173, 699-703.
39. Shulman, L.N. (1995) Plasma cell diseases and related disorders. In: Blood, Principles and Practice of Hematology (ed. by R.I. Handin, S.E. Lux & T.P. Stossel), pp. 885-915. J.B. Lippincott Company, Philadelphia.
40. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Anti-tumour activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565-1571.
41. Smith, M.R., Xie, T., Joshi, I. & Schilder, R.J. (1998) Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. British Journal of Haematology, 102, 1090-1097.
42. Uchiyama, H., Barut, B.A., Mohrbacher, A.F., Chauhan, D. & Anderson, K.C. (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82, 3712-3720.
43. Urashima, M., Ogata, A., Chauhan, D., Hatziyanni, M., Vidriales, M.B., Dedera, D.A., Schlossman, R.L. & Anderson, K.C. (1996) Transforming growth factor-β: differential effects on multiple myeloma versus normal B cells. Blood, 87, 1928-1938.
44. Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F. & Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology, 87, 503-508.
45. Weber, D.M., Gavino, M., Delasalle, K., Rankin, K., Giralt, S. & Alexanian, R. (1999) Thalidomide alone or with dexamethasone for multiple myeloma. Blood, 94(Suppl. 1), 604a.